2017 Fiscal Year Final Research Report
New strategy for oral cancer treatment by control of long non-coding RNA
| Project/Area Number |
15K11300
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
國安 弘基 奈良県立医科大学, 医学部, 教授 (00253055)
桐田 忠昭 奈良県立医科大学, 医学部, 教授 (70201465)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | Oral cancer / long non-coding RNA / malic enzyme |
|---|
| Outline of Final Research Achievements |
Malic enzyme 1 (ME1) is a multifunctional protein involved in energy production and overexpressed in various cancers. We examined expression and function of ME1 in oral squamous cell carcinomas (OSCC). Immunohistochemical expression of ME1 was moderated to strong in 48% of OSCCs and correlated with pT, pN clinical stage and histological grade. Moderate to strong ME1 expression indicated a worse prognosis than did weak ME1 expression. Malic enzyme 1 knockdown or inactivation by lanthanide inhibited cell proliferation and mortility and suppressed the epithelial-mesenchymal transition in HSC3 human OSCC cells. Knockdown of ME1 also shifted energy metabolism from aerobic glycolysis and lactate fermentation to mitochondrial oxidative phosphorylation and the redox status from reductive to oxidative. In a mouse tumor model, lanthanide suppressed tumor growth and increased survival time. These findings reveal that ME1 is a valid target for molecular therapy in OSCC.
|
| Free Research Field |
oncology
|
